.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,144,549

« Back to Dashboard

Claims for Patent: 9,144,549

Title:Methods and devices for providing prolonged drug therapy
Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.
Inventor(s): Gupta; Suneel K. (Palo Alto, CA), Guinta; Diane R (Palo Alto, CA), Christopher; Carol A. (Palo Alto, CA), Saks; Samuel R. (Palo Alto, CA), Hamel; Lawrence G. (Palo Alto, CA)
Assignee: ALZA CORPORATION (Palo Alto, CA)
Application Number:13/801,000
Patent Claims: 1. A method for treating Attention Deficit Disorder or Attention Deficit Hyperactivity Disorder in a subject that comprises administering a pharmaceutically acceptable composition comprising methylphenidate or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier to a patient in a manner that achieves an ascending release rate of said methylphenidate beginning with a first periodic interval that begins at time t=0 and continuing through about 5.5 hours following said administration.

2. A method for treating Attention Deficit Disorder or Attention Deficit Hyperactivity Disorder in a subject comprising orally administering a dosage form to said subject, wherein said dosage form comprises an immediate release coating comprising methylphenidate hydrochloride; and a sustained release portion comprising methylphenidate hydrochloride and a pharmaceutically acceptable carrier, wherein: said dosage form provides release of said methylphenidate hydrochloride over a period comprising first, second, third, and fourth sequential, one-hour time intervals; and said sustained release portion releases more of said methylphenidate hydrochloride during said second interval than during said first interval, more of said methylphenidate hydrochloride during said third interval than during said second interval, and more of said methylphenidate hydrochloride during said fourth interval than during said third interval.

3. The method according to claim 2 wherein said dosage form is administered one time per day for multiple days.

4. The method according to claim 2 wherein said dosage form is administered to a non-adult subject.

5. The method according to claim 2 wherein said dosage form is a non-osmotic dosage form.

6. The method according to claim 2 wherein said dosage form is an osmotic dosage form.

7. The method according to claim 2 wherein the methylphenidate hydrochloride in said immediate release coating is released primarily during said first interval.

8. A method for treating Attention Deficit Disorder or Attention Deficit Hyperactivity Disorder in a subject comprising orally administering a dosage form to said subject, wherein said dosage form comprises an immediate release portion comprising methylphenidate or a pharmaceutically effective salt thereof; and a sustained release portion comprising methylphenidate or a pharmaceutically effective salt thereof and a pharmaceutically acceptable carrier, wherein: said dosage form releases said methylphenidate over a period comprising first, second, and third sequential one-hour time intervals, and said sustained release portion releases more of said methylphenidate during said second interval than during said first interval, and more of said methylphenidate during said third interval than during said second interval.

9. The method according to claim 8 wherein said period of release comprises a fourth sequential time interval, and wherein the sustained release portion releases more of said methylphenidate during said fourth interval than during said third interval.

10. The method according to claim 8 wherein the methylphenidate released during said first interval only includes methylphenidate released from said immediate release portion.

11. The method according to claim 10 wherein said immediate release portion is applied as a coating on an outer surface of the dosage form.

12. The method according to claim 11 wherein the dosage form releases more of said methylphenidate during said second interval than during said first interval, not including methylphenidate released from said coating during said first interval.

13. The method according to claim 12 wherein the methylphenidate released during said first interval only includes methylphenidate released from said coating.

14. The method according to claim 8 wherein said immediate release portion and said sustained release portion comprise methylphenidate hydrochloride.

15. The method according to claim 8 wherein said dosage form is a non-osmotic dosage form.

16. The method according to claim 8 wherein said dosage form is an osmotic dosage form.

17. The method according to claim 8 wherein the methylphenidate hydrochloride in said immediate release coating is released primarily during said first interval.

18. A method for treating Attention Deficit Disorder or Attention Deficit Hyperactivity Disorder in a subject comprising orally administering a dosage form to said subject, wherein said dosage form comprises: an immediate release portion comprising methylphenidate or a pharmaceutically effective salt thereof; and a sustained release portion comprising methylphenidate or a pharmaceutically effective salt thereof and a pharmaceutically acceptable carrier, wherein said dosage form provides a substantially ascending blood plasma concentration of said methylphenidate or pharmaceutically effective salt thereof from 2.5 hours following administration to 5.5 hours following administration.

19. The method according to claim 18 wherein said immediate release portion and said sustained release portion each comprise D-methylphenidate.

20. The method according to claim 18 wherein said immediate release portion and said sustained release portion each comprise methylphenidate hydrochloride.

21. The method according to claim 18 wherein said dosage form provides a substantially ascending blood plasma concentration of said methylphenidate or pharmaceutically effective salt thereof from 1.5 to 5.5 hours following administration.

22. The method according to claim 18 wherein said dosage form provides a blood plasma concentration of said methylphenidate or pharmaceutically effective salt thereof that is greater at about 8 hours following administration than at 4 hours following administration.

23. The method according to claim 18 wherein said blood plasma at a time up to 4 hours following administration comprises said methylphenidate or pharmaceutically effective salt thereof from said immediate release portion.

24. The method according to claim 18 wherein said blood plasma at a time after 4 hours following administration does not comprise methylphenidate or pharmaceutically effective salt thereof from said immediate release portion.

25. The method according to claim 18 wherein said dosage form is a non-osmotic dosage form.

26. The method according to claim 18 wherein said dosage form is an osmotic dosage form.

27. The method according to claim 18 wherein the methylphenidate hydrochloride in said immediate release coating is released primarily during said first interval.

28. The method according to claim 18 wherein said dosage form provides a substantially ascending blood plasma concentration of said methylphenidate or pharmaceutically effective salt thereof from 2.5 hours following administration to 6.5 hours following administration.

29. The method according to claim 18 wherein said dosage form provides a substantially ascending blood plasma concentration of said methylphenidate or pharmaceutically effective salt thereof from 2.5 hours following administration to 8 hours following administration.

30. The method according to claim 18 wherein said dosage form provides a substantially ascending blood plasma concentration of said methylphenidate or pharmaceutically effective salt thereof from 1.5 hours following administration to 8 hours following administration.

31. The method according to claim 18 wherein said dosage form provides a blood plasma concentration of said methylphenidate or pharmaceutically effective salt thereof that is greater at about 8 hours following administration than at 2.5 hours following administration.

32. A method for treating Attention Deficit Disorder or Attention Deficit Hyperactivity Disorder in a subject comprising orally administering a dosage form to said subject, wherein said dosage form comprises: an immediate release portion comprising methylphenidate or a pharmaceutically effective salt thereof; and a sustained release portion comprising methylphenidate or a pharmaceutically effective salt thereof and a pharmaceutically acceptable carrier, wherein said dosage form provides a substantially ascending blood plasma concentration of said methylphenidate or pharmaceutically effective salt thereof from 2.5 hours following administration to 5.5 hours following administration and wherein: said dosage form releases said methylphenidate over a period comprising at least a first and a second sequential time intervals, and said sustained release portion releases more of said methylphenidate during said first interval than during said second interval.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc